Cellular Adjuvants for Viral Infection
US-2024299521-A1 · Sep 12, 2024 · US
Use of FLT3 ligand for enhancing immune responses in RNA immunization
US9486519B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9486519-B2 |
| Application number | US-200913139034-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 9, 2009 |
| Priority date | Dec 10, 2008 |
| Publication date | Nov 8, 2016 |
| Grant date | Nov 8, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).
First claim
Opening claim text (preview).
The invention claimed is: 1. An immunogenic preparation, which comprises: (i) isolated mRNA that codes for at least one antigen that induced an immune response in a mammal, and (ii) an immune response intensifying compound that consists of Fms-like tyrosine kinase 3 ligand (Flt3 ligand), wherein said Flt3 ligand is present in an amount effective to enhance the immune response induced by the at least one antigen by at least 10% as compared to an immune response elicited by the isolated mRNA without said immune response intensifying compound. 2. The immunogenic preparation as claimed in claim 1 , wherein the isolated mRNA is synthetic. 3. The immunogenic preparation as claimed in claim 1 , which further comprises at least one RNA-stabilizing factor. 4. A pharmaceutical composition that comprises an immunogenic preparation as claimed in claim 1 in a pharmaceutically compatible diluent or a pharmaceutically compatible vehicle, or both. 5. The pharmaceutical composition as claimed in claim 4 in the form of a formulation as a vaccine. 6. The pharmaceutical composition as claimed in claim 4 in the form of a formulation for intranodal administration.
Assignees
Inventors
Classifications
Antivirals · CPC title
Fusion polypeptide · CPC title
Growth factors; Growth regulators · CPC title
Antibacterial agents · CPC title
Immunostimulants · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9486519B2 cover?
- The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).
- Who is the assignee on this patent?
- Sahin Ugur, Türeci Özlem, Kreiter Sebastian, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).